|
|
||||||||
EDITORIALS
Jeffrey A. Cohen and Jack P. Antel
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
Article topics:
Related Articles
This article has been cited by other articles:
![]() |
P. Veugelers, J. Fisk, M. Brown, K. Stadnyk, I. Sketris, T. Murray, and V. Bhan Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation Multiple Sclerosis, November 1, 2009; 15(11): 1286 - 1294. [Abstract] [PDF] |
||||
![]() |
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology, October 9, 2007; 69(15): 1498 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch Neurol, April 1, 2006; 63(4): 611 - 614. [Full Text] [PDF] |
||||
![]() |
Interferon-{beta} Therapy for Secondary Progressive Multiple Sclerosis Journal Watch Neurology, February 11, 2005; 2005(211): 4 - 4. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||